1. Pink Sheet
  2. >>Vaccines

Shingrix Gets China Nod But Won’t Launch Until 2020 Amid Strong Demand

 
• By Brian Yang

Following a priority review, Shingrix may become the next hit vaccine in China as millions seek preventative care, but GSK is being cautious over supply plans.

A selective focus at the end of syringe while needle was injected into deltoid muscle and using the cotton to stop bleeding while pulling the needle out
GSK'S SHINGRIX COULD BECOME BEST-SELLING VACCINE IN CHINA • Source: Shutterstock

Shingrix has gained an approval from China’s National Medical Products Administration (NMPA) after an expedited review, but UK-based manufacturer GlaxoSmithKline PLC says the shingles vaccine won’t be launched in the country until 2020.

Already approved elsewhere including in the US, where it was launched in 2017, and in Canada, the EU, Australia and Japan, Shingrix generated sales of £357m ($463.8m) for the company in the first quarter in 2019, rapidly becoming a star product

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet